Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,761 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial.
Zhang T, Howard L, Koontz BF, Tagawa ST, Nagar H, Bitting RL, Frizzell BA, Nordquist L, Rasmussen J, Riggan C, Reyes M, Davies C, Gray SR, Newman CR, Fernandez E, Ramalingam S, Harrison MR, George DJ, Wu Y, Armstrong AJ. Zhang T, et al. Among authors: howard l. Eur Urol Oncol. 2024 Jul 5:S2588-9311(24)00160-3. doi: 10.1016/j.euo.2024.06.013. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38971644
Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy.
Freedland SJ, Choeurng V, Howard L, De Hoedt A, du Plessis M, Yousefi K, Lam LL, Buerki C, Ra S, Robbins B, Trabulsi EJ, Shah NL, Abdollah F, Feng FY, Davicioni E, Dicker AP, Karnes RJ, Den RB. Freedland SJ, et al. Among authors: howard l. Eur Urol. 2016 Oct;70(4):588-596. doi: 10.1016/j.eururo.2016.01.008. Epub 2016 Jan 21. Eur Urol. 2016. PMID: 26806658 Free article.
Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group.
Teeter AE, Griffin K, Howard LE, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. Teeter AE, et al. Among authors: howard le. J Urol. 2018 Mar;199(3):713-718. doi: 10.1016/j.juro.2017.08.107. Epub 2017 Sep 1. J Urol. 2018. PMID: 28870860
Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index.
Aminsharifi A, Howard L, Wu Y, De Hoedt A, Bailey C, Freedland SJ, Polascik TJ. Aminsharifi A, et al. Among authors: howard l. J Urol. 2018 Oct;200(4):758-766. doi: 10.1016/j.juro.2018.05.016. Epub 2018 Jul 6. J Urol. 2018. PMID: 29758219
A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.
Freedland SJ, Howard L, Allen J, Smith J, Stout J, Aronson W, Inman BA, Armstrong AJ, George D, Westman E, Lin PH. Freedland SJ, et al. Among authors: howard l. Prostate Cancer Prostatic Dis. 2019 Sep;22(3):428-437. doi: 10.1038/s41391-019-0126-5. Epub 2019 Jan 21. Prostate Cancer Prostatic Dis. 2019. PMID: 30664736 Clinical Trial.
1,761 results